Evicenter
P&T meetings

Imlifidase

Kidney transplantation in highly sensitized patients

Manufacturer
Hansa Biopharma
Regulatory submission
BLA submitted December 2025
Last updated
85 sources

Product information and disease descriptionProduct descriptionProduct information

Contraindications/Warnings/Precautions/Adverse effects

5 evidence topics · 4 sources

Warnings and precautions
Serious adverse reactions

“The most common serious adverse reactions in clinical studies were pneumonia (5.6%) and sepsis (3.7%).” (opens the source at this quote in a new tab)

Selected contraindications

“Ongoing serious infection.” (opens the source at this quote in a new tab)

“Thrombotic thrombocytopenic purpura (TTP).” (opens the source at this quote in a new tab)

Identified risks and infection prevention

“Severe or serious infection” (opens the source at this quote in a new tab)

“Infusion-related reactions” (opens the source at this quote in a new tab)

“To minimise the risk of infections, all patients should receive treatment with antibiotics.” (opens the source at this quote in a new tab)

Interference with alloantibody screening: case report

“Following imlifidase treatment, alloantibody screening prior to blood transfusion returned a false-negative result” (opens the source at this quote in a new tab)

Interference with protein electrophoresis and immunofixation

“In conclusion, imlifidase is a new exogenous substance that interferes with SPE, ISE and IFE in a new way.” (opens the source at this quote in a new tab)